- Home
- ATCH vs QLGN Comparison
ATCH vs QLGN Comparison
Compare ATCH & QLGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATCH
- QLGN
- Stock Information
- Founded
- ATCH 2022
- QLGN 1996
- Country
- ATCH United States
- QLGN United States
- Employees
- ATCH N/A
- QLGN N/A
- Industry
- ATCH
- QLGN Biotechnology: Pharmaceutical Preparations
- Sector
- ATCH
- QLGN Health Care
- Exchange
- ATCH Nasdaq
- QLGN Nasdaq
- Market Cap
- ATCH 3.0M
- QLGN 2.8M
- IPO Year
- ATCH N/A
- QLGN N/A
- Fundamental
- Price
- ATCH $0.19
- QLGN $3.54
- Analyst Decision
- ATCH
- QLGN
- Analyst Count
- ATCH 0
- QLGN 0
- Target Price
- ATCH N/A
- QLGN N/A
- AVG Volume (30 Days)
- ATCH 2.7M
- QLGN 9.1K
- Earning Date
- ATCH 05-16-2025
- QLGN 08-13-2025
- Dividend Yield
- ATCH N/A
- QLGN N/A
- EPS Growth
- ATCH N/A
- QLGN N/A
- EPS
- ATCH 2.67
- QLGN N/A
- Revenue
- ATCH N/A
- QLGN N/A
- Revenue This Year
- ATCH N/A
- QLGN N/A
- Revenue Next Year
- ATCH N/A
- QLGN N/A
- P/E Ratio
- ATCH $0.07
- QLGN N/A
- Revenue Growth
- ATCH N/A
- QLGN N/A
- 52 Week Low
- ATCH $0.18
- QLGN $2.85
- 52 Week High
- ATCH $66.00
- QLGN $29.44
- Technical
- Relative Strength Index (RSI)
- ATCH 34.16
- QLGN 44.87
- Support Level
- ATCH $0.18
- QLGN $3.37
- Resistance Level
- ATCH $0.20
- QLGN $3.85
- Average True Range (ATR)
- ATCH 0.02
- QLGN 0.23
- MACD
- ATCH 0.01
- QLGN -0.03
- Stochastic Oscillator
- ATCH 10.53
- QLGN 34.29
About ATCH AtlasClear Holdings Inc. Common Stock
AtlasClear Holdings Inc is a fintech company. Its goal is to build a cutting-edge technology-enabled financial services firm that would create a more efficient platform for trading, clearing, settlement, and banking of evolving and innovative financial products with a focus on financial services firms. It is a fintech-driven business-to-business platform that expects to power innovation in fintech, investing, and trading. The company believes it is positioned to provide a modern, mission-critical suite of solutions to its clients, enabling them to reduce their transaction costs and compete more effectively in their businesses.
About QLGN Qualigen Therapeutics Inc.
Qualigen Therapeutics Inc is a early-clinical-stage therapeutics company focused on developing treatments for adult and pediatric cancer. The company's business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program. The company's lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells.